The mechanism of topoisomerase I poisoning by a camptothecin analog
AUTOR(ES)
Staker, Bart L.
FONTE
National Academy of Sciences
RESUMO
We report the x-ray crystal structure of human topoisomerase I covalently joined to double-stranded DNA and bound to the clinically approved anticancer agent Topotecan. Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor. The structure can explain several of the known structure–activity relationships of the camptothecin family of anticancer drugs and suggests that there are at least two classes of mutations that can produce a drug-resistant enzyme. The first class includes changes to residues that contribute to direct interactions with the drug, whereas a second class would alter interactions with the DNA and thereby destabilize the drug-binding site.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=137726Documentos Relacionados
- Targeted disruption of the mouse topoisomerase I gene by camptothecin selection.
- The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I.
- Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin–oligonucleotide conjugates
- DNA sequence selectivity of human topoisomerase I-mediated DNA cleavage induced by camptothecin
- Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
